-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Barchart·10/06/2026 06:30:00
Listen to the news

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.